(Total Views: 507)
Posted On: 01/05/2025 5:59:27 AM
Post# of 149104
Nice catch.
Mazen Nourredin was the first-listed author for the rather remarkable poster detailing the results of Cytodyn's earlier MASH study. The poster was shown at EASL's International Liver Conference in London, June 2022.
So yes, he has tremendous knowledge about Leronlimab's abilities vs. MASH. Don't know if that will lead to CYDY presenting at the Park City conference in just four days' time (a little earlier than Sundance). It might well be that CYDY wants to get the results of the follow-up study going on right now before presenting results.
Here's a copy of that poster in case anyone hasn't seen it.
https://www.postersessiononline.eu/173580348_...8274_3.png
Mazen Nourredin was the first-listed author for the rather remarkable poster detailing the results of Cytodyn's earlier MASH study. The poster was shown at EASL's International Liver Conference in London, June 2022.
So yes, he has tremendous knowledge about Leronlimab's abilities vs. MASH. Don't know if that will lead to CYDY presenting at the Park City conference in just four days' time (a little earlier than Sundance). It might well be that CYDY wants to get the results of the follow-up study going on right now before presenting results.
Here's a copy of that poster in case anyone hasn't seen it.
https://www.postersessiononline.eu/173580348_...8274_3.png
(6)
(0)Scroll down for more posts ▼
